Key facts
- This page summarizes Hans Hull's Form 4 filing for PLIANT THERAPEUTICS, INC. (PLRX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 19 Jul 2023, 20:26.
Hans Hull - 17 Jul 2023 Form 4 Insider Report for PLIANT THERAPEUTICS, INC. (PLRX)
- Reporting relationship
- Chief Business Officer
- Issuer ticker
- PLRX
- Reported as of
- 17 Jul 2023
- Net transaction value
- -$323,029
- SEC form
- 4
- Accepted by SEC
- 19 Jul 2023, 20:26:30 UTC
- Prior SEC filing
- 18 Jul 2023
- Next SEC filing
- 07 Aug 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mike Ouimette, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Hans Hull filed Form 4 for PLIANT THERAPEUTICS, INC. (PLRX) on 19 Jul 2023.
Change
- Previous filing in this sequence was filed on 18 Jul 2023.
- Current net transaction value: -$323,029.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PLRX
transaction
Common Stock
Sale
- Transaction value
- $323,029
- Shares
- -17,937
- Change %
- -7.6%
- Price
- $18.01
- Shares after
- 219,183
- Date
- 17 Jul 2023
- Ownership
- Direct
- Footnotes
- F1
PLRX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 3,821
- Date
- 17 Jul 2023
- Ownership
- See footnote
- Footnotes
- F2
PLRX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 13,985
- Date
- 17 Jul 2023
- Ownership
- See footnote
- Footnotes
- F3
PLRX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 13,985
- Date
- 17 Jul 2023
- Ownership
- See footnote
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 4 footnotes
Footnote F1
Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $17.63 to $18.47, inclusive, between July 17, 2023 and July 19, 2023 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4.
Footnote F2
The shares are held by The Sloger Hull Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for the purposes of Section 16 or for any other purpose.
Footnote F3
The shares are held by a trust for the Reporting Person's minor child ("Child A Trust"). The Reporting Person and his spouse serve as trustees for Child A Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Footnote F4
The shares are held by a trust for the Reporting Person's minor child ("Child B Trust"). The Reporting Person and his spouse serve as trustees for Child B Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.